Vertex and Parion Sciences to Co-Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis
Vertex Pharmaceuticals Incorporated and Parion Sciences recently announced a joint collaboration for the development of investigational epithelial sodium channel (ENaC) inhibitors to treat cystic fibrosis (CF) and other pulmonary conditions. Based on the agreement rights, Vertex will develop and commercialize Parion’s ENaC inhibitors, named P-1037 and P-1055, for…